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Background: MicroRNAs (miRNAs) are coordinators of cellular differentiation, including granulopoiesis. Although
differential expression of many miRNAs is associated with the maturation of granulocytes, analysis of differentially
expressed miRNAs and their cellular localization across all stages of granulopoiesis, starting from hemopoietic
stems cells, is not well characterized.
Methods: We analyzed whole cell miRNA and mRNA expression during granulopoiesis using Taqman low-density
and Affymetrix arrays respectively. We also performed nuclear and cytoplasmic fractionation followed by Taqman
low-density array and/or quantitative PCR to identify nuclear-enriched miRNAs in hemopoietic stem/progenitor cells,
promyelocytes, myelocytes, granulocytes and several hemopoietic cell lines. Anti-correlation between the expression
of miRNA and target pairs was used to determine putative miRNA targets.
Results: Analyses of our array data revealed distinct clusters of differentially expressed miRNAs that are specific
to promyelocytes and granulocytes. While the roles of many of these miRNAs in granulopoiesis are not currently
known, anti-correlation of the expression of miRNA/mRNA target pairs identified a suite of novel target genes.
Clusters of miRNAs (including members of the let-7 and miR-17-92 families) are downregulated in hemopoietic
stem/progenitor cells, potentially allowing the expression of target genes known to facilitate stem cell proliferation
and homeostasis. Additionally, four miRNAs (miR-709, miR-706, miR-690 and miR-467a*) were found to be enriched
in the nucleus of myeloid cells and multiple hemopoietic cell lines compared to other miRNAs, which are
predominantly cytoplasmic-enriched. Both miR-709 and miR-706 are nuclear-enriched throughout granulopoiesis
and have putative binding sites of extensive complementarity downstream of pri-miRNAs. Nuclear enrichment
of miR-467a* is specific to hemopoietic stem/progenitors and promyelocytes. These miRNAs are also
nuclear-enriched in other hemopoietic cell lines, where nuclear sequestering may fine-tune the expression
of cytoplasmic mRNA targets.
Conclusions: Overall, we have demonstrated differentially expressed miRNAs that have not previously been
associated with hemopoietic differentiation and provided further evidence of regulated nuclear-enrichment of
miRNAs. Further studies into miRNA function in granulocyte development may shed light on fundamental
aspects of regulatory RNA biology and the role of nuclear miRNAs.
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MicroRNAs (miRNAs) are 22-24 nucleotide non-coding
RNAs that participate in the regulation of mRNA expres-
sion in eukaryotes [1-3], and play critical roles in a wide
range of biological processes including cell-cycle control
[4,5], immune response [6-8], and differentiation [9-11].
One of the best-characterized differentiation processes is
granulopoiesis, in which hemopoietic myeloid progenitor
cells develop sequentially from myeloblasts into morpho-
logically distinct promyelocytes, myelocytes and mature
granulocytes. This process is tightly controlled by changes
in the expression of hundreds of transcription factors
[12,13], which are in turn regulated by a few highly
expressed miRNAs, including miR-223 and miR-146a,
both of which have been shown to promote granulopoiesis
[14-16]. Total loss of miR-223 does not completely block
granulopoiesis [14], suggesting that other miRNAs may
also act in concert to maintain this process. Few studies,
however, have sought to completely profile differentially
expressed miRNAs during granulopoiesis in primary cells.
Prior work has either been restricted to differentiated cell
lines [17,18], in which accurate modelling of the specific
stages of granulopoiesis is not entirely possible, or human
neutrophil maturation [19,20].
In the most well-accepted models, miRNAs bind loosely
to complementary sequences in the 3′UTR of their target
mRNAs in the cytoplasm, and function by inhibiting
translation, inducing mRNA cleavage or mRNA degrad-
ation following decapping and deadenylation [21]. It is im-
portant to correlate the expression of miRNAs and their
target mRNAs during granulopoiesis in order to obtain in-
sights into the role of these molecules in the development
of granulocytes. While previous studies have investigated
this relationship in human cells [22], the miRNA-mRNA
interaction network in mouse granulopoiesis has been
largely uncharacterized.
Several studies have reported localization of miRNAs
in the nucleus [23-31], suggesting these molecules may
have other biological functions or mechanisms of action
apart from their canonical role. For example, miRNAs
have been shown to target gene promoters, potentially
inducing overexpression (miR-373) or downregulation
(miR-320) of target genes [32,33]. More recently, mouse-
specific miR-709 was found to be enriched in the nucleus
to target pri-miR-15a and pri-miR-16, thus regulating the
expression of mature miR-15a and miR-16 [31]. With one
exception [31], studies on nuclear-enriched miRNAs have
been performed in cell lines. It remains unclear whether
nuclear enrichment of some miRNAs is a feature of trans-
formed cells, and whether differential expression of nuclear
miRNAs is important in regulating gene expression during
cellular differentiation or transformation.
In this study, we analyzed miRNA expression in pri-
mary murine myeloid cells at four successive stages ofhemopoietic differentiation; Lin− Sca1+ cKit+ stem/pro-
genitor cells (LSK), promyelocytes, myelocytes and gran-
ulocytes. We not only performed analyses of miRNA
expression levels in whole cells, allowing direct inter-
rogation of miRNA-mRNA expression relationships,
but also analyzed purified nuclear and cytoplasmic
cell fractions to profile miRNA subcellular localization.
We found four nuclear-enriched miRNAs in primary cells
and further assessed their subcellular distribution in a
range of mouse hemopoietic cell lines.
Results
Differential expression of whole cell miRNAs during
primary murine granulopoiesis
We first used Taqman Low Density Quantitative Reverse
Transcription PCR array (TLDA RT-qPCR) to determine
the expression of 585 mature mouse and rat miRNAs in
whole cell RNA from four primary murine hemopoietic
populations: LSK, promyelocytes, myelocytes and gra-
nulocytes (Figure 1). A previous report showed that
RT-qPCR results are only reliable when the cycle thresh-
old (CT) is less than 30 [34], and therefore we only
considered the differential expression of miRNAs when
the CT value was <30 in at least one cell type. 129 mouse
miRNAs showed differential expression by 2-fold or more
between two or more stages of murine granulocytic differ-
entiation (Additional file 1). An unsupervized hierarchical
clustering analysis revealed 37 highly expressed miRNAs
(CT <25 in at least one cell type) that were differentially
regulated between two or more differentiation stages
(Figure 2A). Of these, we observed that several had
been previously identified as key modulators of granulo-
poiesis in human and mouse, including miR-223, miR-16,
and miR-29a [14,35,36].
Comparison of our data with a recently reported
miRNA expression profile of human granulopoiesis [19],
restricted to the 64 differentially expressed miRNAs
interrogated by both human and mouse TLDA experi-
ments, indicated a significant correlation between the
expression of miRNAs during mouse and human granu-
lopoiesis (Figure 2B; R2 = 0.5499, P < 0.001). Of 78 miR-
NAs that were upregulated in mouse granulocytes
compared to promyelocytes (fold change >2), 41 were
interrogated in the human TLDA assay, and 30 (73%)
were upregulated (Additional file 2). Similarly, 36 miR-
NAs were downregulated in mouse granulocytes (fold
change < -2) and 23 of these (64%) were common to
both datasets and also downregulated in human samples
(Additional file 2).
Identification of miRNA targets in primary murine
myeloid cells
We next examined mRNA expression using Affyme-
trix microarray analysis for each of the four murine
CD34
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Figure 1 Purification of LSK cells, promyelocytes, myelocytes and granulocytes from mouse bone marrow. Gating strategy for
fluorescence activated cell sorting (FACS) of promyelocytes (red arrow), myelocytes (left box, blue arrow) and granulocytes (right box, blue arrow)
(A), LSK (B), and the total purity of each cell population based on re-analysis following FACS (C) are shown. Promyelocytes, myelocytes and
granulocytes were deposited onto poly-L-lysine slides, stained using May-Grünwald Giemsa, and morphology examined using a light microscope
at 100× magnification (D). Scale bars indicate 10 μm.
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and granulocytes). We then used these data to determine
the possible miRNA targets that were differentially
regulated during granulopoiesis (promyelocytes vs gra-
nulocytes) using our method based on conserved anti-
correlation [37]. There were 67 predicted mRNA targets
in our microarray dataset that demonstrated an inverse
correlation with the expression of an individual miRNA
(Additional file 3). mRNA targets that showed inversely
correlated expression with miRNAs (Additional file 3)
include previously validated miRNA/target pairs such as
Mef2c with miR-223 [14], Bcl2 with miR-15 or miR-16
[38], Mybl2 with miR-29 or miR-30 family members [39],
and Ezh2 with miR-26a [40]. In order to identify miRNA-
target signatures that may distinguish stem and commit-
ted myeloid progenitor cells (LSK vs granulocytes), we
again searched for differentially expressed miRNAs and
their targets that demonstrated inverse correlation in ex-
pression levels. A subset of miRNAs were downregulated
in LSKs compared to promyelocytes including members
of the let-7 family and the polycistronic mir-17-92 cluster
(Additional file 4). These miRNAs also shared common
targets including Hlf, Mycn and Klf12 (Additional file 4).
We then further refined our analysis to concentrate on
miRNA/target pairs that displayed expression patternsspecific to one stage of granulopoiesis (Figure 3). Expres-
sion of a group of 9 miRNAs, which showed the highest
level of expression in promyelocytes (Figure 3A), was
inversely correlated with a total of 22 predicted or previ-
ously confirmed mRNA targets (Figure 3C). Expression
of 21 granulocyte-enriched miRNAs (Figure 3B) was
inversely correlated with the downregulation of 125 puta-
tive or confirmed mRNA targets (Figure 3C).
Nuclear and cytoplasmic localization of miRNAs in murine
myeloid cells
In order to determine the sub-cellular localization of miR-
NAs, we performed nuclear and cytoplasmic fractionation
on LSK, promyelocytes, myelocytes and granulocytes,
extracted the RNA, and analyzed miRNA expression by
TLDA RT-qPCR (Figure 4). Purity of nuclear and cyto-
plasmic fractions was determined using RT-qPCR to
assess the expression of the nuclear specific SnoRNA19,
which was enriched in the nuclear RNA samples by 8- to
56-fold (Figures 4 and 5A), and Y1 cytoplasmic RNA,
which was enriched in the cytoplasmic RNA pools by 4-
to 9-fold (Figure 5A). Western blot was also performed to
confirm the purity of nuclear and cytoplasmic fractions
(Figure 5A). The nuclear lamina protein, Lmnb1 and the
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Figure 2 miRNA expression during mouse and human
granulopoiesis. (A) Differentially expressed miRNAs between two
or more stages of granulopoiesis. Heatmap shows highly expressed
miRNAs (CT < 25 in at least one cell type) that displayed differential
expression between two or more cell types. The level of miRNA
expression is represented by a color scale where yellow indicates
lower-level expression, orange indicates medium expression and red
indicates higher expression. (B) Correlation between the expression
levels of differentially-expressed miRNAs during mouse and human
granulopoiesis. A significant correlation was found between the
fold-differential expression of 64 miRNAs common to both mouse
and human datasets (P < 0.001, Spearman’s correlation). Prom;
promyelocytes. Myel; myelocytes, Gran; granulocytes.
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ity of these fractions. Almost all miRNAs were distributed
towards the upper left quadrant, confirming that the
vast majority of miRNAs are enriched in the cytoplasm
(Figure 4). Linear regression analysis of miRNAs showed
correlation of the miRNA cytoplasmic and nuclear expres-
sion levels (R2 = 0.7185-0.8666) suggesting that the low
level of nuclear expression (relative to cytoplasmic expres-
sion) is predominantly due to low level contamination of
the nuclear fraction with cytoplasmic miRNAs.
In order to determine whether some miRNAs were
bona fide nuclear expressed, we focused on the ~60
mature miRNAs that were expressed in the nucleus of at
least one cell type with a CT < 30 (Additional file 5). The
majority of highly-expressed miRNAs (CT < 30) displayed
nuclear: cytoplasmic ratio of <0.1, indicating there was
10-fold more miRNA expression in the cytoplasm
compared to the nucleus. We performed additional
regression analysis of the ratio of nuclear to cytoplasmic
expression of miRNAs and found six highly-expressed
miRNAs (CT < 30) that trended towards being nuclear-
enriched (ratio nuclear: cytoplasmic expression > 0.1)
in one or more cell types. Amongst these 6 miRNAs,
miR-706 and miR-467a* (now renamed miR-467a-3p)
had nuclear:cytoplasmic ratios > 1 in promyelocytes
(Additional file 5).
We next performed individual Taqman miRNA RT-
qPCR assays to validate the nuclear enrichment of these six
miRNAs (miR-706, miR-467a*, miR-709, miR-690, miR-
135a* (now renamed miR-135a-1-3p) and miR-142-3p)
compared to that of highly cytoplasmic-enriched control
miRNAs identified in the TLDA assays in (Figures 4
and 5B). Three of these (miR-706, miR-709 and miR-690)
were found to be enriched in the nucleus of all four cell
types studied (ratio nuclear:cytoplasmic expression was
significantly greater that of the mean nuclear-cytoplasm of
controls, p < 0.05). Expression of miR-467a*, interestingly,
was enriched only in the nucleus of LSK and promyelo-
cytes, while expression of miR-135* and miR-142-3p did
not appear to be nuclear-enriched in any myeloid popula-
tion (Figure 5B).
Nuclear expression of miR-709, miR-706, miR-690 and
miR-467a* in hemopoietic cell lines
In order to characterize the extent of the nuclear expres-
sion of these miRNAs, we analyzed the expression of
miR-709, miR-706, miR-690 and miR-467a* in four
mouse hemopoietic cell lines: MPRO, EL4, MEL and
A20. The purity of the subcellular fractions was con-
firmed using RT-qPCR (Figure 5A), as described above.
The nuclear:cytoplasmic expression of miR-709, miR-
706 and miR-690 was significantly greater in the nucleus
of all four cell lines compared to cytoplasmic-enriched
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Figure 3 (See legend on next page.)
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Figure 3 Stage specific changes in miRNA expression throughout granulopoiesis and their putative targets in promyelocytes and
granulocytes. miRNAs that were expressed highest in promyelocytes (A) or granulocytes (B) are shown together with their predicted targets
according to TargetScan (C). Targets were only displayed if they were expressed lowest in the same tissue where miRNA expression was the
highest. This facilitates the visualization of putative miRNA-mRNA pairs that were specific to promyelocytes or granulocytes. #, Target mRNAs that
are known validated targets (Tarbase) of the stage specific miRNAs.
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A20 (p < 0.05) (Figure 5C).
Predicted pri-miRNA targets of nuclear-enriched miR-709,
miR-706, miR-467a* and miR-690
A previous study has shown that miR-709 is nuclear-
enriched and targets other pri-miRNAs in the nucleus,
thereby downregulating the expression of their mature
forms [31]. Therefore, these nuclear-enriched miRNAs
detected in hemopoietic cells may act as negative regula-
tors of other miRNAs. We predicted pri-miRNA targets
of the four nuclear-enriched miRNAs: miR-709, miR-
706, miR-467a* and miR-690 during mouse granulopoi-
esis using RNAhybrid [41]. We correlated the expression
of nuclear-enriched miRNAs with the expression of
mature miRNAs (in the cytoplasm), in cases where theirLSKs





















































Figure 4 Cytoplasmic:nuclear expression of miRNAs in primary mouse
analysis from LSK cells, promyelocytes, myelocytes and granulocytes are sh
miRNAs. Solid line indicates linear regression analysis of miRNA expression
nuclear CT (increased nuclear expression) are labelled. Y1 RNA CT (cytoplasprimary transcripts were predicted targets of each of the
four nuclear-enriched miRNAs. We only considered
candidates that were predicted to hybridize with res-
pective nuclear-enriched miRNAs with a minimum free
energy (MFE) of < -30 kcal/mol, and a high probability
of binding as determined using RNAcalibrate (p < 0.05)
[41]. Upregulation of miR-709 from promyelocytes to
granulocytes correlated with the downregulation of ma-
ture miR-20b and miR-92a (Figure 6A); putative binding
sites of both pri-miRNA-20b and 92a demonstrated near
perfect complementarity to mature miR-709 (Figure 6B).
Downregulation of nuclear-enriched miR-706 from pro-
myelocytes to granulocytes occurred in conjunction
with the upregulation of 7 mature miRNAs (Figure 6A).
Of these 7 miRNAs, miR-142 and miR-192 possessed
putative binding sites in their primary transcripts thatPromyelocytes























































myeloid cells. CT data from cytoplasmic and nuclear TLDA miRNA
own based on cell equivalent volumes to detect nuclear-enriched
with goodness of fit (R2) values shown. miRNAs showing decreased
mic control) and SnoRNA CT (nuclear control) are also shown.
Log2 nuclear:cytoplasm




























































































































































































































































































































































































































































































NucCyt NucCyt NucCyt NucCyt NucCyt NucCyt
NucCyt NucCyt NucCyt NucCyt NucCyt NucCyt NucCyt
Figure 5 Nuclear enrichment of miRNAs in primary mouse myeloid cells and hemopoietic cell lines. (A) RT-qPCR of known nuclear- and
cytoplasmic-specific RNA in nuclear and cytoplasmic RNA fractions in mouse primary cells and cell lines. Lower panels show representative western
blots for nuclear-specific Lmnb1 and cytoplasmic-specific Gapdh protein in the nuclear and cytoplasmic fractions. Both RT-qPCR and western blotting
confirm the range of detection and enrichment of nuclear and cytoplasmic fractions (B) Nuclear-enriched miR-709, miR-706, miR-467a* and miR-690 in
primary mouse LSK cells, promyelocytes, myelocytes and granulocytes. (C) Nuclear-enriched miRNAs in mouse hemopoietic cell lines, MPRO, EL4,
MEL and A20. (* P < 0.05; ** P < 0.01, t-test). Prom; promyelocytes. Myel; myelocytes, Gran; granulocytes.
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(Figure 6B). The expression of nuclear-enriched miR-
690 and miR-467a* did not show anti-correlation with
that of mature miRNAs processed from their putative
pri-miRNA targets (Figure 6A).
Validation of miRNA function in the nucleus
In order to study whether miR-706 can target pri-miRNAs
(like miR-709) [31], we transfected cell lines with a
miRNA inhibitor and examined mature target miRNA
levels. Using a labelled miRNA, we achieved >95%
transfection efficiency (Figure 7A), although expressionwas limited to the cytoplasm (Figure 7B). miRNA in-
hibitors can either bind to and degrade the mature
miRNA, resulting in lower miRNA levels by RT-
qPCR, or form a stable heteroduplex [42], which can
inhibit function while still allowing detection by RT-
qPCR. Analysis of miR-706 levels showed no signifi-
cant decrease in expression, suggesting that this inhibitor
may form a heteroduplex (Figure 7C). However, inhibition
of miR-706 function did not lead to a significant increase
in the expression of predicted miRNA targets in MEL
cells (Figure 7C). Analysis of miR-706 knockdown in
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Figure 6 Predicted pri-miRNA targets of nuclear-enriched miR-709, miR-706, miR-467a* and miR-690 during mouse granulopoiesis.
(A) Heatmaps showing differential expression of nuclear miRNAs (name in red) in promyelocytes, myelocytes and granulocytes together with
the expression of mature miRNAs (name in black; inverse correlated in blue), processed from predicted pri-miRNAs targets of respective
nuclear-enriched miRNAs. (B) Putative binding site for miR-709 on pri-miR-20b and pri-miR-92a, and miR-706 on pri-miR-142 and pri-miR-192 as
predicted by RNAhybrid. Near perfect complementarity between nuclear-enriched miRNA and putative pri-miRNA target was found in each case.
Wong et al. Journal of Hematology & Oncology 2014, 7:42 Page 8 of 15
http://www.jhoonline.org/content/7/1/42levels, however this increase was not statistically sig-
nificant (Figure 7C).
We also considered that miRNAs may be retained in
the nucleus to prevent them from targeting mRNAs in
the cytoplasm. Relevant to our study, miR-709 has previ-
ously been shown to target Myc, which is downregulated
during myeloid cell differentiation [43]. We observed
higher expression of cytoplasmic miR-709 in granulocytes
(CT: 20.432) compared to promyelocytes (CT: 21.599)
(Additional file 5) suggesting that a greater amount of
miR-709 may be present in mature granulocytes to se-
quester Myc expression. miR-706 has previously been
shown to regulate the expression of myeloid transcription
factor Stat1 [44]. We therefore determined its expression
in myeloid cell lines MEL and MPRO following inhibition
of miR-706. Knockdown of miR-706 resulted in a signifi-
cant upregulation of Stat1 by 6 to 8-fold in both cell lines,indicating its role in the regulation of this transcription
factor (P < 0.05) (Figure 7D). It is therefore possible that
retention of miR-706 in the nucleus, which would result
in decreased cytoplasmic miR-706 expression, may act to
fine-tune expression of target genes such as Stat1.
Discussion
Previous studies have shown the involvement of several
miRNAs in granulopoiesis including miR-223 [14], miR-
34a [45], and miR-146a [16]. However, a systematic
expression profiling of miRNAs and their mRNA targets
across successive populations of myeloid cells at defined
stages of granulopoiesis is lacking. Comprehensive miRNA
expression profiling of human granulocytic differentiation
was recently published, and showed that the potential
roles of many miRNAs in granulopoiesis, either individu-
ally or as a group, are currently ignored [19,20].
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Figure 7 The effect of miR-706 inhibition on the expression of putative target miRNAs and mRNAs in MEL and MPRO cells.
(A) Representative plots showing high efficiencies of transfection of Dy547-labelled inhibitor control in MEL and MPRO cells (right) compared to
non-transfected controls (left), indicating that miR-706 hairpin is likely to be transfected at similar high efficiencies. (B) Immunofluorescent microscopy
of MEL cells showing cytoplasmic localization of transfected inhibitor control (red), with nuclei counterstained by Hoechst 33342 (blue). (C) Expression
of miR-706, miR-142-3p, miR-532, miR-192 and miR-194 in cells transfected with miR-706 hairpin inhibitor compared to control. (D) Expression of Stat1
in MEL and MPRO cells transfected with miR-706 inhibitor and control. (*P < 0.05; **P < 0.01, t-test).
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characterization of miRNA expression across carefully
purified cells at progressive stages of murine granulopoi-
esis. In addition, we correlated miRNA expression with
their predicted and confirmed mRNA targets to deter-
mine the possible role of differentially expressed miRNAs
during granulopoiesis.
Amongst miRNAs that showed differential expression
between mouse promyelocytes and granulocytes, we noted
many that have been shown to be associated with
hematological malignancies (Figure 2A). Several miRNAsthat were upregulated during granulopoiesis (miR-15a,
miR-16 and miR-29) have previously been shown to be
downregulated in acute myeloid leukemia [46,47]. miR-
NAs that were downregulated during granulopoiesis,
including miR-17, miR-19a and miR-20a, were amongst
those previously shown to be upregulated in leukemia
[48]. These data suggest the control of miRNA expression
is crucial in ensuring proper cell differentiation, and failure
of this control may lead to, or contribute to, cancer.
Many miRNAs that we identified as being differentially
expressed in granulopoiesis were not previously implicated
Wong et al. Journal of Hematology & Oncology 2014, 7:42 Page 10 of 15
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26a, miR-26b, miR-93, miR-106b, miR-191, miR-139-5p,
miR-140 and miR-195 (Figures 2A and 3, Additional file 1).
Notably, several miRNAs shared common predicted tar-
gets with miRNAs that are known to be important for
granulopoiesis (Additional file 3). For example, miR-106b
and miR-194 were predicted to target the transcription fac-
tor gene, Mef2c, which is a confirmed target of miR-223
[14,49]. Repression of Mef2c is important for early gra-
nulopoiesis and may also be involved in the regulation of
granulocyte activation [14]. Expression of miR-106b and
miR-194 may act in concert with that of miR-223, which
may explain a previous observation whereby granulopoiesis
was not completely impaired in miR-223 null mice [14].
A recent study reported a plethora of differentially
expressed miRNAs during human granulopoiesis, many
of which were predicted in silico to target key transcrip-
tion factors such as Runx1 and Pu.1 [20]. Our stringent
analysis that considered anti-correlation between miRNA
and mRNA target expression did not reveal any miRNAs
predicted to regulate key transcription factors such as
Cebpα, Pu.1 or Runx1 during granulopoiesis, suggesting
that essential transcription factors are not likely to be
directly regulated by miRNAs during this process (data
not shown). However, the transcription factor Myb
was downregulated with concurrent overexpression of
miR-15b, miR-16, miR-150 and miR-195 (Figure 3
and Additional file 3). Myb is involved in hemopoietic
progenitor proliferation [50], and may need to be down-
regulated to allow terminal differentiation of granulocytes.
We also observed downregulation of transcription factors
such as Mga and Tcf4, and myeloid leukemia related genes
including Pml, Abl1, and Bcl11a in terminally differenti-
ated granulocytes in conjunction with the expression of a
group of granulocyte-enriched miRNAs (Figure 3). Future
studies are required to determine whether downregulation
of these genes is important for normal granulopoiesis and
whether they are regulated by miRNAs.
Several members of the polycistronic miR-17-92 cluster
and the homologous miR-106a-92 cluster (miR-17, miR-
19a, miR-20a, miR-92a and miR-106a) were expressed at
the highest levels in promyelocytes (Figure 3B). These
miRNAs are known to have oncogenic potential and are
overexpressed in hematological malignancies [48,51,52].
Overexpression of these miRNAs is also known to confer
a stem cell-like phenotype [51]. While our data was con-
sistent with others in that these miRNAs were highly
expressed in early developmental lineages [51], it was
surprising that their expression levels were lower in LSK
compared to promyelocytes. These data are the first to in-
dicate that the miR-17-92 polycistron is predominantly
over-expressed in promyelocytes during granulopoiesis. In
relation to leukaemia, overexpression of miR-17-92 may
reflect accumulation of blast cells and promyelocytes inmyeloid malignancies such as acute and chronic myeloid
leukemia [53]. Furthermore, we and others have previ-
ously shown that miR-17-92 expression is downregulated
following imatinib treatment in chronic myeloid leukae-
mia patients [54,55]; this observation may reflect the
normalization of blood cell proportions following hemato-
logical response after treatment [56]. In line with previous
reports [57,58], we detected downregulation of confirmed
miR-17-92 targets including Pten and E2f2 in promye-
locytes compared to granulocytes (Additional file 3),
although the significance of this observation in the context
of granulopoiesis remains unclear.
Consistent with others [59-61], we found the highest
expression of miR-125a, mir-125b, let7d and let7e in
LSK and promyelocytes compared to differentiated cells
(Additional file 1). In addition, our present data indicate
the downregulation of miR-17-92 and let-7 families in
LSK compared to promyelocytes, in conjunction with
the overexpression of their reciprocal targets including
hepatic leukemia factor (Hlf ), V-myc myelocytomatosis
viral related oncogene (Mycn) and krüppel-like factor 12
(Klf12) (Additional file 4). Hlf is a transcription factor
that can confer anti-apoptotic effects and prevent pre-
mature death of hemopoietic stem cells [62]. Mycn is an
oncogene which is important for the proliferation and
homeostasis of stem cells [63]. The role of the trans-
cription factor, Klf12 in stem cell development is as yet
unknown. However, other members of krüppel-like factor
family such as Klf4 and Klf5 are key players in em-
bryonic stem cell renewal and somatic cell reprogram-
ming [64,65]. Whether Klf12 has a role similar to Klf4 and
Klf5 remains to be elucidated.
We have also carefully purified the nuclear and cyto-
plasmic RNA from four populations of murine primary
hemopoietic cells to study the localization of miRNAs in
these cells. This step is important given the recent
reports of nuclear-enriched miRNAs that could possibly
be involved in non-canonical functions [32,33]. These
miRNAs are unlikely to regulate gene expression by
targeting the 3′ UTR of target mRNAs but may target
the promoter of genes [32,33], or other pri-miRNAs
[31]. Alternatively, these miRNAs may be retained in the
nucleus to prevent them from downregulating a potential
target mRNA in the cytoplasm [23].
It is important to consider the fact that perfect
nuclear/cytoplasmic fractionation is technically difficult
and thus rigid analysis is required to obtain meaningful
data [30]. We only considered the highly expressed
miRNAs in each sample (expression was detected below
30 cycles of RT-qPCR amplification in at least one cell
type) to minimize possible false positive results. Further-
more, by using cell equivalent volumes, and comparing to
the mean expression of cytoplasmic enriched miRNAs, we
further reduced false positive results. Our discovery of
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in primary mouse liver, where three nuclear-enriched
miRNAs were found [31]. These data suggest that the
majority of miRNAs are acting in a canonical manner by
targeting the 3′UTR of granulopoiesis-regulating genes. It
is also noteworthy that the majority (73%) of the differen-
tially expressed miRNAs are conserved between mouse
and human (Figure 2B and Additional file 2), and this
could mean they are likely to have common canonical
mRNA targets [66].
All four nuclear-enriched miRNAs, miR-709, miR-706,
miR-690 and miR-467a* in hemopoietic cells are mouse
specific miRNAs. It is interesting to note the enrichment
of miR-706 and miR-467a* in the nucleus of primary
mouse hemopoietic cells and cell lines because these
miRNAs have not been reported as being nuclear-
enriched in other cell types [23-31]. Notably, the primary
transcript of miR-142-3p, a miRNA recently found to be
important in promoting granulopoieisis, was amongst
the putative targets of miR-706 (Figure 6B). In contrast
to the previous finding in mouse liver, we did not
observe an anti-correlation between the expression of
nuclear miR-709 and cytoplasmic miR-15a/16 in myeloid
cells. We discovered two other predicted pri-miRNA
targets of miR-709 based on our in silico analysis using
RNAhybrid and anti-correlation of miRNA expression.
This result suggests that interaction between this nu-
clear-enriched miRNA and its pri-miRNA targets may
be cell type specific. Inhibition of miR-706 in MEL and
MPRO cells, however, did not result in significant accu-
mulation of predicted miRNA targets, indicating either
these miRNAs are not the actual targets or nuclear
miR-706 may not function by targeting pri-miRNA
transcripts. Alternatively, since the miRNA inhibitor
was expressed in the cytoplasm, it is possible that there
was little to no reduction in nuclear miR-706 expression
levels in these cells. Whether miR-706 and other nuclear-
enriched miRNAs target pri-miRNAs during hemopoiesis
remains to be determined.
miRNAs may also be retained in the nucleus to fine-tune
the expression of their mRNA target(s). Apart from the
validated role of miR-709 in regulating the expression of
Myc, knockdown of miR-690 has recently been shown to
increase the expression of a key myeloid transcription fac-
tor Cebpα [67]. Consistent with others [44], we have shown
that miR-706 regulates the expression of Stat1; a transcrip-
tion factor involved in myeloid differentiation. The reten-
tion of miR-709, miR-690 and miR-706 in the nucleus may
be important to control the expression of transcription
factors or other proteins during granulopoiesis.
Conclusions
Overall, we have provided a comprehensive characteri-
zation of miRNAs and mRNA target expression duringmouse granulopoiesis, as well as examining the global
nuclear and cytoplasmic abundance of miRNAs during
granulopoiesis. Furthermore, we have examined the nu-
clear and cytoplasmic expression of miRNAs in mouse
primary myeloid cells and hemopoietic cell lines. We
showed that miRNAs are predominantly expressed in the
cytoplasm of primary myeloid cells from mouse and thus,
they are likely to induce canonical post-transcriptional
gene silencing by targeting 3′UTRs. There were four
nuclear-enriched miRNAs that are ubiquitously present
in mouse hemopoietic cells, including two miRNAs,
miR-467a* and miR-706 that have never been reported to
be nuclear-enriched. These miRNAs may be constrained
to the nucleus to fine-tune the expression of their mRNA
targets. We have also provided a comprehensive profiling
of miRNAs and their targets in the course of murine
granulopoiesis, which highlights clusters of miRNAs that
may be regulating this process. Conditional knockout of
Dicer-1 in myeloid progenitors has recently been descri-
bed [68]. Dicer-1 depletion leads to neutrophil dysplasia
with marked loss of expression of a large number of
miRNAs. Amongst these are those differentially regulated
in our study including miR-16, miR-19a, miR-26a,
miR-26b, miR-139, miR-195 and miR-223. The roles
of many of these miRNAs and their targets in granulopoi-
esis are currently unknown and are therefore interesting
candidates for future studies.
Materials and Methods
Primary cells and cell lines
Bone marrow was harvested from the femur, tibia
and spine of C57BL/6 mice as previously described
[69-71]. Primary mouse hemopoietic stem/progenitor
cells (Lin−Sca1+cKit+; LSK), promyelocytes, myelocytes
and granulocytes were isolated using established fluo-
rescence–activated cell sorting (FACS) protocols [71-73].
For the isolation of LSK cells, bone marrow cells
were incubated with lineage specific antibodies (B220,
Ter119, CD3, Gr-1, CD11b; BioLegend), conjugated to
biotin, together with anti–Sca1–fluorescein isothiocyan-
ate (FITC; Biolegend) and anti–cKit–phycoerythrin (PE;
Becton Dickinson). Antibodies used for the isolation of
promyelocytes, myelocytes and granulocytes were lineage
specific antibodies (B220, CD19, CD3, Sca1; BioLegend),
conjugated to biotin, together with anti–Gr–1–FITC
(Biolegend), anti–cKit–PE (Becton Dickinson), anti–CD34–
Alexafluor 647 (eBioscience) and anti–CD16/32–PerCP/
Cy5.5 (Becton Dickinson) antibodies. Cells were washed
twice in PBS with 2% (v/v) FCS and incubated with strep-
tavidin–APC–Cy7 (Biolegend). Control stains for FITC,
PE, PerCP/Cy5.5, Alexafluor 647 and APC–Cy7 were used
to determine compensation settings and gating for each
population. The FACS gating strategies for the four cell
types are shown in Figure 1A and B.
Wong et al. Journal of Hematology & Oncology 2014, 7:42 Page 12 of 15
http://www.jhoonline.org/content/7/1/42Purity of over 84% was achieved for all cell types
(Figure 1C). Morphological confirmation of promyelo-
cytes, myelocytes and granulocytes was performed follow-
ing May-Grünwald Giemsa staining of cells spun onto
poly-L-lysine slides (Figure 1D).
MEL and EL4 cells were grown in Dulbecco’s Modified
Eagle's Medium (DMEM) supplemented with 10% fetal
calf serum (FCS). A20 cells were maintained in RPMI
1640 media containing 10% FCS. MPRO cells were main-
tained in DMEM media supplemented with 5% FCS
plus 10% BHK-HM5 conditioned medium. All growth
media was supplemented with 5 U/mL penicillin, 5 μg/ml
streptomycin sulfate and 2 mM L-glutamine.
Preparation of nuclear, cytoplasmic and total RNA
Nuclear and cytoplasmic fractions were separated using
the PARIS kit (Ambion) with RNAse inhibitors to
minimize RNA degradation. RNA was extracted from
either the nucleus, cytoplasm or whole cells using Trizol
(Invitrogen) according to the manufacturer’s instruc-
tions. Purity of the nuclear and cytoplasmic RNA was
confirmed by comparing the abundance of snoRNA or
Y1 cytoplasmic RNA using quantitative PCR (qPCR) as
previously described [26,29].
Western blot to assess the purity of the nuclear and
cytoplasmic fractions
Nuclear and cytoplasmic cell lysates were loaded onto
precast SDS-PAGE gels (Invitrogen) and transferred
onto PVDF membranes. Membranes were blocked with
5% skim milk and incubated overnight at 4°C with a
polyclonal rabbit anti-Lmnb1 antibody (1:5,000; Abcam)
or monoclonal mouse anti-Gapdh antibody (1:1,000;
Abcam), followed by a HRP-conjugated secondary anti-
rabbit or anti-mouse antibody (1:5,000; Chemicon). HRP-
conjugated antibodies were detected using enhanced
chemiluminescence reagents (Pierce) on a Kodak Imager
(Kodak).
Taqman low-density array
Taqman low-density array (TLDA) was performed using
TaqMan® Array Rodent MicroRNA A + B Cards Set v2.0
(Applied Biosystems) as previously described [55]. Sam-
ples used were whole cell, cytoplasmic and nuclear RNA
from LSK, promyelocytes, myelocytes and granulocytes.
Briefly, reverse transcription reaction was performed
using rodent Megaplex™ RT primers (Applied Biosystems),
which contain a pool of 750 individual miRNA-specific
primers, according to the manufacturer’s instructions.
Real-time quantitative PCR (RT-qPCR) was then carried
out on an ABI 7900HT real-time PCR machine with the
LDA thermal cycler block, using pre-defined TLDA
thermal cycling conditions. RT-qPCR data were analyzed
using SDS 2.3 and RQ Manager Software (AppliedBiosystems). The whole cell and cytoplasmic miRNA CT
values correlated with R2 values of 0.9126 (LSK), 0.9112
(promyelocyte), 0.9244 (myelocyte) and 0.9406 (granulo-
cyte). Raw data were deposited in the Gene Expression
Omnibus database (accession number GSE57624).
Microarray and data analysis
Differential expression of mRNAs during differentiation
of hemopoietic stem/progenitor cells into granulocytes
was determined using Affymetrix GeneChip Gene 1.0
ST mouse arrays according to the manufacturers’ in-
structions. Briefly, 300 ng of total RNA from 3 biological
replicates of LSK cells, promyelocytes, myelocytes or
granulocytes was used for the synthesis of double-
stranded cDNA using random hexamers tagged with
a T7 promoter sequence. Amplification of the double-
stranded cDNA was then performed using T7 RNA
polymerase to produce cRNA. cRNA was subjected to
a first-strand cDNA synthesis with incorporation of
dUTP residues to produce single-stranded DNA. Frag-
mentation of single-stranded DNA was subsequently
performed using a mixture of uracil DNA glycosylase and
apurinic/apyrimidinic endonuclease 1, which can recog-
nize unnatural dUTP residues and induce breakage to the
DNA. Single-stranded DNA was assessed using RNA
6000 Nano Chip on an Agilent 2100 Bioanalyzer (Agilent
Technologies), and successfully fragmented DNA was
labelled with terminal deoxynucleotidyl transferase with a
DNA labelling reagent (Affymetrix). Samples were injec-
ted into Affymetrix array chips and hybridized at 45°C and
60 rpm for 17 hours in a hybridization oven (Affymetrix).
Arrays were stained and washed in the Affymetrix Gene-
Chip Fluidic Station 450 and scanned using Affymetrix
GeneChip Scanner 3000 7G.
The arrays were normalized using the justRMA suite of
algorithms from Bioconductor (http://www.bioconductor.
org/). Genes with a minimal fold change in expression of
2 and a moderated P-Value of 0.05 using empirical Bayes
shrinkage were considered significantly differentially ex-
pressed as previously reported [74]. Raw data were depos-
ited in the Gene Expression Omnibus database (accession
number GSE57624).
Bioinformatics analyses
mRNA and miRNA expression across samples was
compared and negative correlations were determined as
previously published [37]. All mRNA/miRNA pairs with
significant changes in expression between promyelocytes
and granulocytes in opposite directions were considered
as potential functional interactors. These pairs were
filtered further by requiring a perfect match between the
seed region of each miRNA and the 3′UTR of the paired
mRNA. These seed matches were either an 8mer match,
a 7mer-m8 site or a 7mer-A1 site.
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Quantitative TaqMan® MicroRNA Assay (Applied Bio-
systems) was performed according to the manufacturer’s
instructions using primer and probes that specifically de-
tect individual miRNAs of interest. For the measurement
of miRNA expression in the nuclear and cytoplasmic frac-
tions, a total of 6 μl was used for each cell-equivalent frac-
tion of nuclear and cytoplasmic RNA. Fold expression of
miRNA in the nucleus was calculated as a ratio over its
expression in the cytoplasm.
Prediction of pri-miRNA targets of nuclear-enriched miRNAs
Putative pri-miRNA targets of nuclear-enriched miRNAs
were predicted using RNAhybrid (http://bibiserv.techfak.
uni-bielefeld.de/rnahybrid) [41]. Primary transcripts of
all miRNAs annotated in miRBase were considered in
this analysis.
Inhibition of miR-706 function
MEL and MPRO cells were transfected with the 2′-O-
methylated miRIDIAN mmu-miR-706 hairpin inhibitor
(Thermo Scientific) or the miRIDIAN miRNA hairpin
inhibitor transfection control with Dy547. The optimal
concentration of inhibitor for each cell type was deter-
mined based on the percentage of Dy547-positive cells
measured using a BD Biosciences LSR Fortessa Analyzer
following transfection with different concentrations of
dye-labelled control. The optimal concentration of in-
hibitor for MEL and MPRO were 80 and 300 nM re-
spectively. For each transfection reaction, 1x10E5 cells
were plated per well in a six-well plate containing 800 μl
of antibiotic-free DMEM with 10% FCS. Inhibitor was
diluted to a final volume of 185 μl with DMEM, while 4
μl Oligofectamine (Invitrogen) was diluted to 15 μl of
DMEM at room temperature for 5 mins. The two mix-
tures were then combined and incubated for another 20
mins at room temperature before being added to the
cells. Transfection mixtures were replaced with fresh
DMEM containing 10% FCS after four hours, and incu-
bated for 48 hours prior to harvest. Immunofluorescent
microscopy was performed using a Leica SP5 Confocal
microscope to determine the localization of Dy547-la-
belled inhibitor control in transfected cells. Total RNA
was extracted and miRNA expression was measured
using individual TaqMan® MicroRNA Assays (Applied
Biosystems). Stat1 expression was measured using stand-
ard RT-qPCR.
Statistical analyses
The significance of fold change in miRNA expression was
analyzed using the Wilcoxon signed rank test applied to
the ΔCT values. Correlation analyses were computed
using the Spearman rank correlation test. Student’s t-tests
were used to compare the expression ratio of nuclear-enriched miRNAs with cytoplasmic enriched controls.
T-tests were also used to compare the expression of
Stat1 in cell lines transfected with miR-706 inhibitors
and control. Analyses were performed using GraphPad
Prism v.5 (La Jolla, CA, USA). Results were considered
significant when P value < 0.05.Additional files
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